Special care is needed in myelosuppression, renal and hepatic impairment. Elderly patients should use the drug with special case. Monitor patients with risk factors for liver disease. Blood tests should be carried out regularly. Monitor serum CK concentration in patients who have received treatment more than 6 months. Contact the doctor if muscle weakness, shortness of breath or symptoms of hepatitis or pancreatitis occurs. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.